

**TO**

All Providers, HMOs and Other Managed Care Organizations

REGARDING

Coverage of Moderna COVID-19 Vaccine for Members Aged 6 Through 17 Years

Coverage of Moderna COVID-19 Vaccine for Members Aged 6 Through 17 Years

Effective for dates of service on and after June 24, 2022, ForwardHealth covers the following Current Procedural Terminology procedure codes for the Moderna COVID-19 vaccine for members aged 6 through 17 years.

PROCECURE CODE FOR MEMBERS AGED 6-11 YEARS	DESCRIPTION
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years
0093A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years

PROCEDURE CODE FOR MEMBERS AGED 12-17 YEARS	DESCRIPTION
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

Additional information is available in the following ForwardHealth publications:

- ForwardHealth Update [2021-01](#), titled “COVID-19 Vaccine Billing and Reimbursement”
- ForwardHealth Update [2021-09](#), titled “COVID-19 Vaccine Policy and Coverage Clarifications”
- ForwardHealth Alert [036](#), titled “Reimbursement Rate Increase for COVID-19 Vaccine Administration”

COVID-19-related ForwardHealth Alerts and Updates are available on the [COVID-19: ForwardHealth News and Resources](#) page of the ForwardHealth Portal.